

Genome UK

Considerations on data security, sharing and analysis

Genome UK — The Three Pillars


- ▷ Pillar 1: Diagnosis and Personalised Medicine
 - ▶ Improve the diagnosis, stratification and treatment of illness.
- ▷ Pillar 2: Prevention
 - ▶ Enabling predictive and preventative care.
- ▷ Pillar 3: Research
 - ▶ Supporting fundamental and translational research.

👉 The success of Genome UK will rely on the public's willingness to share highly sensitive data for research and clinical applications.

Genome sequences: the bulk of the data

- ▶ **Genome UK:** Goal of generating WGS data for 1.5 M individuals → 150 Pb data.
 - ▶ Hardware and software infrastructure for data security and data sharing security essential.
- ▶ **PetaGene:** Experience supporting customers across Life Sciences in managing genomic data.
 - ▶ We can help Genome UK ensure successful implementation.

Genome UK – our key recommendations



Key opportunities

Genomic Data is sensitive

- ▶ Public willingness to share data is declining ([Ghafur, S. et al 2020 Lancet](#)).
- ▶ Controlled, secure data access is fundamental to maintaining public trust.
- ▶ Sharing a person's whole genome, exome or chromosome is unnecessarily invasive since usually a very small portion (< 0.1%) is sufficient.
- ▶ Data minimisation: share only minimum necessary information for each purpose.
 - ▶ Italy, Slovakia, US HIPAA explicitly enforce in research. Collection explicit in UK law.
 - ▶ Unnecessary sharing significantly increases de-anonymisation risks.
 - ▶ Share only genetic regions relevant for analyses. Audit all access, and by purpose.
- ▶ Ideally, give each individual control of data & visibility into how their data is being used.

Key opportunities

Avoid technical barriers

- ▶ Life Sciences stakeholders need to combine existing data and pipelines with new data.
- ▶ Democratise cost of precision medicine.
 - ▶ Implementation of new standards must be *practical, improve performance & not introduce bottlenecks*.
- ▶ Public & private sector have invested billions in R&D building existing pipelines.
 - ▶ Therefore: crucial to keep supporting them.
 - ▶ Exciting new APIs; e.g. GA4GH *htsget* (fully supported by PetaGene).
 - ▶ **But** slow & expensive for fine-grained regional access compared to alternatives.

Key opportunities

Computational Reproducibility is essential

- ▷ Ability to reproduce results for clinical and research purposes.
 - ▶ This is the basis on which scientific advancements are made possible.
- ▷ Ability to continue to use existing containerised, certified workflows with Genome UK data.

Preserving data integrity is key

- ▷ Need to consider strategies to retain data integrity.
- ▷ Minimise loss of information that may become important for accurate analyses in future.



PetaGene

For any questions or inquiries please
contact us at: info@petagene.com